Have you seen the explosion in biotech stocks of late? There may be another in the works.
Applied Genetics Technology Corporation (AGTC) is an ocular gene therapy company that is markedly undervalued given the strength of its lead program and the breadth of its pipeline. The company's science is well-published and the clinical data to date is strong. Data to be presented in January 2020 may propel the stock dramatically.
AGTC's Lead Program Is for a Sizable Market
AGTC is developing gene therapies for rare ophthalmologic disorders. Leading the pipeline is X-linked retinitis